Academic Journal
Προβολή σε EDS

Luteolin as a urease inhibitor: A novel therapeutic strategy against Helicobacter pylori.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Luteolin as a urease inhibitor: A novel therapeutic strategy against Helicobacter pylori.
Συγγραφείς: Wang X; College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China., Zhou D; Jiangxi Province Key Laboratory of Traditional Chinese Medicine Pharmacology, Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang, China.; Jiangxi Health Industry Institute of Traditional Chinese Medicine, Nanchang, China., Li M; College of Integrated Chinese and Western Medicine, Changchun University of Chinese Medicine, Changchun, China., Kong X; Endocrinology Department, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China., Jiang S; School of Basic Medicine, Changchun University of Chinese Medicine, Changchun, China., Li Q; Research Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China., Wei L; School of Basic Medicine, Changchun University of Chinese Medicine, Changchun, China., Jiang L; College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China., Song W; School of Basic Medicine, Changchun University of Chinese Medicine, Changchun, China.
Πηγή: Virulence [Virulence] 2026 Dec; Vol. 17 (1), pp. 2712031. Date of Electronic Publication: 2026 Aug 03.
Τύπος έκδοσης: Journal Article
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101531386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2150-5608 (Electronic) Linking ISSN: 21505594 NLM ISO Abbreviation: Virulence Subsets: MEDLINE
Imprint Name(s): Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin, Tex. : Landes Bioscience
Ιατρικοί όροι (MeSH): Luteolin*/pharmacology , Urease*/antagonists & inhibitors , Urease*/chemistry , Helicobacter pylori*/drug effects , Helicobacter pylori*/enzymology , Helicobacter Infections*/drug therapy , Helicobacter Infections*/microbiology , Enzyme Inhibitors*/pharmacology , Anti-Bacterial Agents*/pharmacology, Bacterial Proteins/antagonists & inhibitors ; Animals ; Mice ; Humans ; Molecular Docking Simulation ; Cell Line ; Disease Models, Animal
Περίληψη: The rising prevalence of antibiotic-resistant Helicobacter pylori (H. pylori) underscores the urgent need for alternative treatment strategies. By producing ammonia to neutralize gastric acid, the key virulence factor urease is essential for H. pylori acid tolerance, thereby representing a promising therapeutic target. In this study, we identified luteolin as a potent urease inhibitor (IC50 = 30.50 μg/mL) from a screening of over 200 natural compounds. Further investigation through molecular docking, dynamics simulations, cellular thermal shift assay, and enzyme kinetics studies confirmed its competitive binding to the Ni2+-centered catalytic site of H. pylori urease (HPU). Luteolin exhibited potent anti-H. pylori activity under standard and simulated gastric conditions, and showed low propensity for resistance development over 14 serial passages. Proteomic and metabolomic analyses revealed that luteolin inhibited HPU activity, and the consequent ammonia restriction triggered severe metabolic dysfunction, characterized by disruptions in nucleotide, amino acid biosynthesis and TCA cycle. In GES-1 cells, luteolin protected against H. pylori-induced damage. In a mouse model of H. pylori-induced peptic ulcer, luteolin treatment significantly reduced the bacterial load, with concomitant alleviation of gastric mucosal pathology and suppression of inflammatory responses. In contrast to antibiotic-induced gastric microbial dysbiosis, microbial diversity analysis indicated that luteolin treatment had minimal impact on the resident gastric microbiota. In summary, as a urease inhibitor, luteolin suppresses H. pylori by blocking ammonia production, thereby disrupting acid neutralization and inducing metabolic dysfunction, which collectively alleviates gastric damage and inflammation while minimizing microbiota disruption and resistance risk.
References: Nat Rev Dis Primers. 2023 Apr 20;9(1):19. (PMID: 37081005)
Nat Rev Cancer. 2010 Jun;10(6):403-14. (PMID: 20495574)
Anal Cell Pathol (Amst). 2019 Apr 4;2019:9506863. (PMID: 31093484)
Front Pharmacol. 2024 Jun 24;15:1430564. (PMID: 38983919)
Int J Mol Sci. 2025 Jun 22;26(13):. (PMID: 40649776)
Biochem Biophys Res Commun. 2003 Oct 24;310(3):715-9. (PMID: 14550260)
Eur J Pharm Sci. 2024 Sep 1;200:106840. (PMID: 38909691)
Dig Dis Sci. 2017 May;62(5):1146-1154. (PMID: 28315035)
Biomed Rep. 2021 Feb;14(2):19. (PMID: 33335725)
J Chem Inf Model. 2022 Aug 8;62(15):3535-3550. (PMID: 35666858)
Infect Immun. 1994 Aug;62(8):3586-9. (PMID: 8039935)
Nucleic Acids Res. 2024 Jul 5;52(W1):W422-W431. (PMID: 38572755)
J Ethnopharmacol. 2018 Oct 28;225:342-358. (PMID: 29801717)
J Agric Food Chem. 2010 Oct 13;58(19):10661-7. (PMID: 20853834)
Drug Metab Pharmacokinet. 2012;27(1):162-8. (PMID: 21931223)
Exp Ther Med. 2014 Sep;8(3):769-774. (PMID: 25120597)
Nature. 2013 Jan 10;493(7431):255-8. (PMID: 23222544)
J Agric Food Chem. 2015 Sep 9;63(35):7700-6. (PMID: 25625345)
J Enzyme Inhib Med Chem. 2020 Dec;35(1):404-413. (PMID: 31880473)
Expert Opin Ther Pat. 2011 Jun;21(6):945-57. (PMID: 21457123)
Antioxidants (Basel). 2024 Dec 13;13(12):. (PMID: 39765858)
Microb Pathog. 2025 Jul;204:107519. (PMID: 40164399)
Helicobacter. 2024 Jul-Aug;29(4):e13130. (PMID: 39152663)
BMC Med. 2024 Dec 23;22(1):598. (PMID: 39710669)
Eur Urol. 1991;20(3):243-7. (PMID: 1726639)
Lab Invest. 2009 Nov;89(11):1291-303. (PMID: 19736546)
FEMS Immunol Med Microbiol. 1996 Jan;13(1):87-94. (PMID: 8821403)
Helicobacter. 2022 Dec;27(6):e12932. (PMID: 36110057)
J Ethnopharmacol. 2024 Jan 10;318(Pt B):117046. (PMID: 37586440)
J Enzyme Inhib Med Chem. 2018 Dec;33(1):1362-1375. (PMID: 30191728)
Front Microbiol. 2016 Nov 22;7:1817. (PMID: 27920755)
Microbiology (Reading). 2025 Mar;171(3):. (PMID: 40072906)
J Ethnopharmacol. 2022 Sep 15;295:115388. (PMID: 35577159)
Gut. 2017 Jan;66(1):6-30. (PMID: 27707777)
Sci Rep. 2018 May 22;8(1):8014. (PMID: 29789574)
Antimicrob Agents Chemother. 2017 May 24;61(6):. (PMID: 28320722)
Sci Rep. 2024 Jul 7;14(1):15619. (PMID: 38972876)
Lancet Gastroenterol Hepatol. 2024 Jan;9(1):56-67. (PMID: 37972625)
J Ethnopharmacol. 2025 Apr 09;345:119569. (PMID: 40054639)
Int Immunopharmacol. 2023 Feb;115:109679. (PMID: 36640711)
Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0024022. (PMID: 35862746)
Folia Microbiol (Praha). 2020 Apr;65(2):275-291. (PMID: 32026288)
Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):317-23. (PMID: 22697063)
Int J Med Microbiol. 2024 Jun;315:151622. (PMID: 38776570)
Infect Genet Evol. 2020 Mar;78:104135. (PMID: 31837482)
Mol Microbiol. 2018 Dec;110(5):761-776. (PMID: 30230643)
Evid Based Complement Alternat Med. 2022 May 9;2022:4476339. (PMID: 35586693)
J Adv Res. 2018 Jan 31;13:51-57. (PMID: 30094082)
Sci Adv. 2020 Jul 22;6(30):eaay9597. (PMID: 32832655)
Cochrane Database Syst Rev. 2016 Apr 19;4:CD003840. (PMID: 27092708)
Front Med (Lausanne). 2022 Mar 24;9:844915. (PMID: 35402425)
Nucleic Acids Res. 2024 Jul 5;52(W1):W324-W332. (PMID: 38686803)
AAPS PharmSciTech. 2021 Apr 14;22(3):133. (PMID: 33855636)
J Cancer Prev. 2014 Jun;19(2):144-51. (PMID: 25337583)
Int J Biol Sci. 2025 May 7;21(8):3397-3415. (PMID: 40520011)
Chem Sci. 2018 Jul 25;9(38):7488-7497. (PMID: 30510674)
Contributed Indexing: Keywords: Helicobacter pylori; ammonia restriction; luteolin; metabolic disruption; urease
Substance Nomenclature: KUX1ZNC9J2 (Luteolin)
EC 3.5.1.5 (Urease)
0 (Enzyme Inhibitors)
0 (Anti-Bacterial Agents)
0 (Bacterial Proteins)
Entry Date(s): Date Created: 20260804 Date Completed: 20260804 Latest Revision: 20260813
Update Code: 20260814
PubMed Central ID: PMC13449824
DOI: 10.1080/21505594.2026.2712031
PMID: 42548046
Βάση Δεδομένων: MEDLINE
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://resolver.ebsco.com/c/fiv2js/result?sid=EBSCO:cmedm&genre=article&issn=21505608&ISBN=&volume=17&issue=1&date=20261201&spage=2712031&pages=2712031&title=Virulence&atitle=Luteolin%20as%20a%20urease%20inhibitor%3A%20A%20novel%20therapeutic%20strategy%20against%20Helicobacter%20pylori.&aulast=Wang%20X&id=DOI:10.1080/21505594.2026.2712031
    Name: Full Text Finder (for New FTF UI) (ns324271)
    Category: fullText
    Text: Full Text Finder
    MouseOverText: Full Text Finder
Header DbId: cmedm
DbLabel: MEDLINE
An: 42548046
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Luteolin as a urease inhibitor: A novel therapeutic strategy against Helicobacter pylori.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Wang+X%22">Wang X</searchLink>; College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.<br /><searchLink fieldCode="AU" term="%22Zhou+D%22">Zhou D</searchLink>; Jiangxi Province Key Laboratory of Traditional Chinese Medicine Pharmacology, Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang, China.; Jiangxi Health Industry Institute of Traditional Chinese Medicine, Nanchang, China.<br /><searchLink fieldCode="AU" term="%22Li+M%22">Li M</searchLink>; College of Integrated Chinese and Western Medicine, Changchun University of Chinese Medicine, Changchun, China.<br /><searchLink fieldCode="AU" term="%22Kong+X%22">Kong X</searchLink>; Endocrinology Department, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.<br /><searchLink fieldCode="AU" term="%22Jiang+S%22">Jiang S</searchLink>; School of Basic Medicine, Changchun University of Chinese Medicine, Changchun, China.<br /><searchLink fieldCode="AU" term="%22Li+Q%22">Li Q</searchLink>; Research Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.<br /><searchLink fieldCode="AU" term="%22Wei+L%22">Wei L</searchLink>; School of Basic Medicine, Changchun University of Chinese Medicine, Changchun, China.<br /><searchLink fieldCode="AU" term="%22Jiang+L%22">Jiang L</searchLink>; College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.<br /><searchLink fieldCode="AU" term="%22Song+W%22">Song W</searchLink>; School of Basic Medicine, Changchun University of Chinese Medicine, Changchun, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101531386%22">Virulence</searchLink> [Virulence] 2026 Dec; Vol. 17 (1), pp. 2712031. <i>Date of Electronic Publication: </i>2026 Aug 03.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101531386 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2150-5608 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221505594%22">21505594 </searchLink><i>NLM ISO Abbreviation: </i>Virulence <i>Subsets: </i>MEDLINE
– Name: PublisherInfo
  Label: Imprint Name(s)
  Group: PubInfo
  Data: <i>Publication</i>: 2015- : Philadelphia, PA : Taylor & Francis<br /><i>Original Publication</i>: Austin, Tex. : Landes Bioscience
– Name: SubjectMESH
  Label: MeSH Terms
  Group: Su
  Data: <searchLink fieldCode="MM" term="%22Luteolin%22">Luteolin*</searchLink>/<searchLink fieldCode="MM" term="%22Luteolin+pharmacology%22">pharmacology</searchLink> <br /><searchLink fieldCode="MM" term="%22Urease%22">Urease*</searchLink>/<searchLink fieldCode="MM" term="%22Urease+antagonists+%26+inhibitors%22">antagonists & inhibitors</searchLink> <br /><searchLink fieldCode="MM" term="%22Urease%22">Urease*</searchLink>/<searchLink fieldCode="MM" term="%22Urease+chemistry%22">chemistry</searchLink> <br /><searchLink fieldCode="MM" term="%22Helicobacter+pylori%22">Helicobacter pylori*</searchLink>/<searchLink fieldCode="MM" term="%22Helicobacter+pylori+drug+effects%22">drug effects</searchLink> <br /><searchLink fieldCode="MM" term="%22Helicobacter+pylori%22">Helicobacter pylori*</searchLink>/<searchLink fieldCode="MM" term="%22Helicobacter+pylori+enzymology%22">enzymology</searchLink> <br /><searchLink fieldCode="MM" term="%22Helicobacter+Infections%22">Helicobacter Infections*</searchLink>/<searchLink fieldCode="MM" term="%22Helicobacter+Infections+drug+therapy%22">drug therapy</searchLink> <br /><searchLink fieldCode="MM" term="%22Helicobacter+Infections%22">Helicobacter Infections*</searchLink>/<searchLink fieldCode="MM" term="%22Helicobacter+Infections+microbiology%22">microbiology</searchLink> <br /><searchLink fieldCode="MM" term="%22Enzyme+Inhibitors%22">Enzyme Inhibitors*</searchLink>/<searchLink fieldCode="MM" term="%22Enzyme+Inhibitors+pharmacology%22">pharmacology</searchLink> <br /><searchLink fieldCode="MM" term="%22Anti-Bacterial+Agents%22">Anti-Bacterial Agents*</searchLink>/<searchLink fieldCode="MM" term="%22Anti-Bacterial+Agents+pharmacology%22">pharmacology</searchLink><br /><searchLink fieldCode="MH" term="%22Bacterial+Proteins%22">Bacterial Proteins</searchLink>/<searchLink fieldCode="MH" term="%22Bacterial+Proteins+antagonists+%26+inhibitors%22">antagonists & inhibitors</searchLink> ; <searchLink fieldCode="MH" term="%22Animals%22">Animals</searchLink> ; <searchLink fieldCode="MH" term="%22Mice%22">Mice</searchLink> ; <searchLink fieldCode="MH" term="%22Humans%22">Humans</searchLink> ; <searchLink fieldCode="MH" term="%22Molecular+Docking+Simulation%22">Molecular Docking Simulation</searchLink> ; <searchLink fieldCode="MH" term="%22Cell+Line%22">Cell Line</searchLink> ; <searchLink fieldCode="MH" term="%22Disease+Models%2C+Animal%22">Disease Models, Animal</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: The rising prevalence of antibiotic-resistant Helicobacter pylori (H. pylori) underscores the urgent need for alternative treatment strategies. By producing ammonia to neutralize gastric acid, the key virulence factor urease is essential for H. pylori acid tolerance, thereby representing a promising therapeutic target. In this study, we identified luteolin as a potent urease inhibitor (IC<subscript>50</subscript> = 30.50 μg/mL) from a screening of over 200 natural compounds. Further investigation through molecular docking, dynamics simulations, cellular thermal shift assay, and enzyme kinetics studies confirmed its competitive binding to the Ni<superscript>2+</superscript>-centered catalytic site of H. pylori urease (HPU). Luteolin exhibited potent anti-H. pylori activity under standard and simulated gastric conditions, and showed low propensity for resistance development over 14 serial passages. Proteomic and metabolomic analyses revealed that luteolin inhibited HPU activity, and the consequent ammonia restriction triggered severe metabolic dysfunction, characterized by disruptions in nucleotide, amino acid biosynthesis and TCA cycle. In GES-1 cells, luteolin protected against H. pylori-induced damage. In a mouse model of H. pylori-induced peptic ulcer, luteolin treatment significantly reduced the bacterial load, with concomitant alleviation of gastric mucosal pathology and suppression of inflammatory responses. In contrast to antibiotic-induced gastric microbial dysbiosis, microbial diversity analysis indicated that luteolin treatment had minimal impact on the resident gastric microbiota. In summary, as a urease inhibitor, luteolin suppresses H. pylori by blocking ammonia production, thereby disrupting acid neutralization and inducing metabolic dysfunction, which collectively alleviates gastric damage and inflammation while minimizing microbiota disruption and resistance risk.
– Name: Ref
  Label: References
  Group: RefInfo
  Data: Nat Rev Dis Primers. 2023 Apr 20;9(1):19. (PMID: <searchLink fieldCode="PM" term="%2237081005%22">37081005)</searchLink><br />Nat Rev Cancer. 2010 Jun;10(6):403-14. (PMID: <searchLink fieldCode="PM" term="%2220495574%22">20495574)</searchLink><br />Anal Cell Pathol (Amst). 2019 Apr 4;2019:9506863. (PMID: <searchLink fieldCode="PM" term="%2231093484%22">31093484)</searchLink><br />Front Pharmacol. 2024 Jun 24;15:1430564. (PMID: <searchLink fieldCode="PM" term="%2238983919%22">38983919)</searchLink><br />Int J Mol Sci. 2025 Jun 22;26(13):. (PMID: <searchLink fieldCode="PM" term="%2240649776%22">40649776)</searchLink><br />Biochem Biophys Res Commun. 2003 Oct 24;310(3):715-9. (PMID: <searchLink fieldCode="PM" term="%2214550260%22">14550260)</searchLink><br />Eur J Pharm Sci. 2024 Sep 1;200:106840. (PMID: <searchLink fieldCode="PM" term="%2238909691%22">38909691)</searchLink><br />Dig Dis Sci. 2017 May;62(5):1146-1154. (PMID: <searchLink fieldCode="PM" term="%2228315035%22">28315035)</searchLink><br />Biomed Rep. 2021 Feb;14(2):19. (PMID: <searchLink fieldCode="PM" term="%2233335725%22">33335725)</searchLink><br />J Chem Inf Model. 2022 Aug 8;62(15):3535-3550. (PMID: <searchLink fieldCode="PM" term="%2235666858%22">35666858)</searchLink><br />Infect Immun. 1994 Aug;62(8):3586-9. (PMID: <searchLink fieldCode="PM" term="%228039935%22">8039935)</searchLink><br />Nucleic Acids Res. 2024 Jul 5;52(W1):W422-W431. (PMID: <searchLink fieldCode="PM" term="%2238572755%22">38572755)</searchLink><br />J Ethnopharmacol. 2018 Oct 28;225:342-358. (PMID: <searchLink fieldCode="PM" term="%2229801717%22">29801717)</searchLink><br />J Agric Food Chem. 2010 Oct 13;58(19):10661-7. (PMID: <searchLink fieldCode="PM" term="%2220853834%22">20853834)</searchLink><br />Drug Metab Pharmacokinet. 2012;27(1):162-8. (PMID: <searchLink fieldCode="PM" term="%2221931223%22">21931223)</searchLink><br />Exp Ther Med. 2014 Sep;8(3):769-774. (PMID: <searchLink fieldCode="PM" term="%2225120597%22">25120597)</searchLink><br />Nature. 2013 Jan 10;493(7431):255-8. (PMID: <searchLink fieldCode="PM" term="%2223222544%22">23222544)</searchLink><br />J Agric Food Chem. 2015 Sep 9;63(35):7700-6. (PMID: <searchLink fieldCode="PM" term="%2225625345%22">25625345)</searchLink><br />J Enzyme Inhib Med Chem. 2020 Dec;35(1):404-413. (PMID: <searchLink fieldCode="PM" term="%2231880473%22">31880473)</searchLink><br />Expert Opin Ther Pat. 2011 Jun;21(6):945-57. (PMID: <searchLink fieldCode="PM" term="%2221457123%22">21457123)</searchLink><br />Antioxidants (Basel). 2024 Dec 13;13(12):. (PMID: <searchLink fieldCode="PM" term="%2239765858%22">39765858)</searchLink><br />Microb Pathog. 2025 Jul;204:107519. (PMID: <searchLink fieldCode="PM" term="%2240164399%22">40164399)</searchLink><br />Helicobacter. 2024 Jul-Aug;29(4):e13130. (PMID: <searchLink fieldCode="PM" term="%2239152663%22">39152663)</searchLink><br />BMC Med. 2024 Dec 23;22(1):598. (PMID: <searchLink fieldCode="PM" term="%2239710669%22">39710669)</searchLink><br />Eur Urol. 1991;20(3):243-7. (PMID: <searchLink fieldCode="PM" term="%221726639%22">1726639)</searchLink><br />Lab Invest. 2009 Nov;89(11):1291-303. (PMID: <searchLink fieldCode="PM" term="%2219736546%22">19736546)</searchLink><br />FEMS Immunol Med Microbiol. 1996 Jan;13(1):87-94. (PMID: <searchLink fieldCode="PM" term="%228821403%22">8821403)</searchLink><br />Helicobacter. 2022 Dec;27(6):e12932. (PMID: <searchLink fieldCode="PM" term="%2236110057%22">36110057)</searchLink><br />J Ethnopharmacol. 2024 Jan 10;318(Pt B):117046. (PMID: <searchLink fieldCode="PM" term="%2237586440%22">37586440)</searchLink><br />J Enzyme Inhib Med Chem. 2018 Dec;33(1):1362-1375. (PMID: <searchLink fieldCode="PM" term="%2230191728%22">30191728)</searchLink><br />Front Microbiol. 2016 Nov 22;7:1817. (PMID: <searchLink fieldCode="PM" term="%2227920755%22">27920755)</searchLink><br />Microbiology (Reading). 2025 Mar;171(3):. (PMID: <searchLink fieldCode="PM" term="%2240072906%22">40072906)</searchLink><br />J Ethnopharmacol. 2022 Sep 15;295:115388. (PMID: <searchLink fieldCode="PM" term="%2235577159%22">35577159)</searchLink><br />Gut. 2017 Jan;66(1):6-30. (PMID: <searchLink fieldCode="PM" term="%2227707777%22">27707777)</searchLink><br />Sci Rep. 2018 May 22;8(1):8014. (PMID: <searchLink fieldCode="PM" term="%2229789574%22">29789574)</searchLink><br />Antimicrob Agents Chemother. 2017 May 24;61(6):. (PMID: <searchLink fieldCode="PM" term="%2228320722%22">28320722)</searchLink><br />Sci Rep. 2024 Jul 7;14(1):15619. (PMID: <searchLink fieldCode="PM" term="%2238972876%22">38972876)</searchLink><br />Lancet Gastroenterol Hepatol. 2024 Jan;9(1):56-67. (PMID: <searchLink fieldCode="PM" term="%2237972625%22">37972625)</searchLink><br />J Ethnopharmacol. 2025 Apr 09;345:119569. (PMID: <searchLink fieldCode="PM" term="%2240054639%22">40054639)</searchLink><br />Int Immunopharmacol. 2023 Feb;115:109679. (PMID: <searchLink fieldCode="PM" term="%2236640711%22">36640711)</searchLink><br />Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0024022. (PMID: <searchLink fieldCode="PM" term="%2235862746%22">35862746)</searchLink><br />Folia Microbiol (Praha). 2020 Apr;65(2):275-291. (PMID: <searchLink fieldCode="PM" term="%2232026288%22">32026288)</searchLink><br />Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):317-23. (PMID: <searchLink fieldCode="PM" term="%2222697063%22">22697063)</searchLink><br />Int J Med Microbiol. 2024 Jun;315:151622. (PMID: <searchLink fieldCode="PM" term="%2238776570%22">38776570)</searchLink><br />Infect Genet Evol. 2020 Mar;78:104135. (PMID: <searchLink fieldCode="PM" term="%2231837482%22">31837482)</searchLink><br />Mol Microbiol. 2018 Dec;110(5):761-776. (PMID: <searchLink fieldCode="PM" term="%2230230643%22">30230643)</searchLink><br />Evid Based Complement Alternat Med. 2022 May 9;2022:4476339. (PMID: <searchLink fieldCode="PM" term="%2235586693%22">35586693)</searchLink><br />J Adv Res. 2018 Jan 31;13:51-57. (PMID: <searchLink fieldCode="PM" term="%2230094082%22">30094082)</searchLink><br />Sci Adv. 2020 Jul 22;6(30):eaay9597. (PMID: <searchLink fieldCode="PM" term="%2232832655%22">32832655)</searchLink><br />Cochrane Database Syst Rev. 2016 Apr 19;4:CD003840. (PMID: <searchLink fieldCode="PM" term="%2227092708%22">27092708)</searchLink><br />Front Med (Lausanne). 2022 Mar 24;9:844915. (PMID: <searchLink fieldCode="PM" term="%2235402425%22">35402425)</searchLink><br />Nucleic Acids Res. 2024 Jul 5;52(W1):W324-W332. (PMID: <searchLink fieldCode="PM" term="%2238686803%22">38686803)</searchLink><br />AAPS PharmSciTech. 2021 Apr 14;22(3):133. (PMID: <searchLink fieldCode="PM" term="%2233855636%22">33855636)</searchLink><br />J Cancer Prev. 2014 Jun;19(2):144-51. (PMID: <searchLink fieldCode="PM" term="%2225337583%22">25337583)</searchLink><br />Int J Biol Sci. 2025 May 7;21(8):3397-3415. (PMID: <searchLink fieldCode="PM" term="%2240520011%22">40520011)</searchLink><br />Chem Sci. 2018 Jul 25;9(38):7488-7497. (PMID: <searchLink fieldCode="PM" term="%2230510674%22">30510674)</searchLink>
– Name: SubjectMinor
  Label: Contributed Indexing
  Group:
  Data: <i>Keywords: </i>Helicobacter pylori; ammonia restriction; luteolin; metabolic disruption; urease
– Name: NumberCAS
  Label: Substance Nomenclature
  Group: ID
  Data: KUX1ZNC9J2 (Luteolin)<br />EC 3.5.1.5 (Urease)<br />0 (Enzyme Inhibitors)<br />0 (Anti-Bacterial Agents)<br />0 (Bacterial Proteins)
– Name: DateEntry
  Label: Entry Date(s)
  Group: Date
  Data: <i>Date Created: </i>20260804 <i>Date Completed: </i>20260804 <i>Latest Revision: </i>20260813
– Name: DateUpdate
  Label: Update Code
  Group: Date
  Data: 20260814
– Name: PubmedCentralID
  Label: PubMed Central ID
  Group: ID
  Data: PMC13449824
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.1080/21505594.2026.2712031
– Name: AN
  Label: PMID
  Group: ID
  Data: 42548046
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=cmedm&AN=42548046
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/21505594.2026.2712031
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2712031
    Subjects:
      – SubjectFull: Bacterial Proteins antagonists & inhibitors
        Type: general
      – SubjectFull: Animals
        Type: general
      – SubjectFull: Mice
        Type: general
      – SubjectFull: Humans
        Type: general
      – SubjectFull: Molecular Docking Simulation
        Type: general
      – SubjectFull: Cell Line
        Type: general
      – SubjectFull: Disease Models, Animal
        Type: general
      – SubjectFull: Luteolin pharmacology
        Type: general
      – SubjectFull: Urease antagonists & inhibitors
        Type: general
      – SubjectFull: Urease chemistry
        Type: general
      – SubjectFull: Helicobacter pylori drug effects
        Type: general
      – SubjectFull: Helicobacter pylori enzymology
        Type: general
      – SubjectFull: Helicobacter Infections drug therapy
        Type: general
      – SubjectFull: Helicobacter Infections microbiology
        Type: general
      – SubjectFull: Enzyme Inhibitors pharmacology
        Type: general
      – SubjectFull: Anti-Bacterial Agents pharmacology
        Type: general
    Titles:
      – TitleFull: Luteolin as a urease inhibitor: A novel therapeutic strategy against Helicobacter pylori.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wang X
      – PersonEntity:
          Name:
            NameFull: Zhou D
      – PersonEntity:
          Name:
            NameFull: Li M
      – PersonEntity:
          Name:
            NameFull: Kong X
      – PersonEntity:
          Name:
            NameFull: Jiang S
      – PersonEntity:
          Name:
            NameFull: Li Q
      – PersonEntity:
          Name:
            NameFull: Wei L
      – PersonEntity:
          Name:
            NameFull: Jiang L
      – PersonEntity:
          Name:
            NameFull: Song W
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2026 Dec
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2150-5608
          Numbering:
            – Type: volume
              Value: 17
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Virulence
              Type: main
ResultId 1